$ACOG
Alpha Cognition Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024098409 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.296M
YoY Change 11.19%
% of Gross Profit
Research & Development $996.0K $1.469M
YoY Change -32.21% -9.27%
% of Gross Profit
Depreciation & Amortization $236.00 $21.12K
YoY Change -98.88% -68.9%
% of Gross Profit
Operating Expenses $2.488M $2.787M
YoY Change -10.73% -0.77%
Operating Profit -$2.488M -$2.766M
YoY Change -10.06%
Interest Expense -$569.2K
YoY Change -177.63%
% of Operating Profit
Other Income/Expense, Net $627.9K $32.76K
YoY Change 1816.6%
Pretax Income -$3.323M
YoY Change 60.14%
Income Tax
% Of Pretax Income
Net Earnings -$1.860M -$3.323M
YoY Change -44.03% 60.14%
Net Earnings / Revenue
Basic Earnings Per Share -$0.31 -$0.84
Diluted Earnings Per Share -$0.31 -$0.03
COMMON SHARES
Basic Shares Outstanding 15.53M shares 150.9M shares 3.880M shares
Diluted Shares Outstanding 6.030M shares 3.880M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $706.9K
YoY Change -81.0%
Cash & Equivalents $3.666M $908.4K
Short-Term Investments
Other Short-Term Assets $381.8K
YoY Change 281.55%
Inventory
Prepaid Expenses $710.3K
Receivables
Other Receivables
Total Short-Term Assets $4.514M $1.145M
YoY Change 294.43% -70.04%
LONG-TERM ASSETS
Property, Plant & Equipment $1.011K $2.250K
YoY Change -55.07% -80.83%
Goodwill
YoY Change
Intangibles $432.7K
YoY Change
Long-Term Investments
YoY Change
Other Assets $80.00K
YoY Change
Total Long-Term Assets $513.7K $554.9K
YoY Change -7.41% -14.2%
TOTAL ASSETS
Total Short-Term Assets $4.514M $1.145M
Total Long-Term Assets $513.7K $554.9K
Total Assets $5.028M $1.699M
YoY Change 195.88% -61.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $790.3K $703.2K
YoY Change 12.39% 30.42%
Accrued Expenses $867.7K
YoY Change 47.79%
Deferred Revenue
YoY Change
Short-Term Debt $1.157M
YoY Change -1.6%
Long-Term Debt Due $1.157M
YoY Change
Total Short-Term Liabilities $3.006M $2.896M
YoY Change 3.78% 25.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $74.25K $4.942M
YoY Change -98.5% 1167.26%
Total Long-Term Liabilities $74.25K $4.942M
YoY Change -98.5% 1167.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.006M $2.896M
Total Long-Term Liabilities $74.25K $4.942M
Total Liabilities $7.948M $7.838M
YoY Change 1.4% 191.19%
SHAREHOLDERS EQUITY
Retained Earnings -$70.63M
YoY Change
Common Stock $49.15M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.920M -$6.138M
YoY Change
Total Liabilities & Shareholders Equity $5.028M $1.699M
YoY Change 195.88% -61.95%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.860M -$3.323M
YoY Change -44.03% 60.14%
Depreciation, Depletion And Amortization $236.00 $21.12K
YoY Change -98.88% -68.9%
Cash From Operating Activities -$1.592M
YoY Change -76.35%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.345M
YoY Change 3197.6%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.294M
YoY Change 4731.02%
NET CHANGE
Cash From Operating Activities -1.592M
Cash From Investing Activities 0.000
Cash From Financing Activities 1.294M
Net Change In Cash -298.2K
YoY Change -95.56%
FREE CASH FLOW
Cash From Operating Activities -$1.592M
Capital Expenditures $0.00
Free Cash Flow -$1.592M
YoY Change -76.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
usd
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2024Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-42403
dei Entity Registrant Name
EntityRegistrantName
Alpha Cognition Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Address Line1
EntityAddressAddressLine1
1200 - 750 West Pender Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V6C
dei City Area Code
CityAreaCode
(604)
dei Local Phone Number
LocalPhoneNumber
564-9244
dei Security12b Title
Security12bTitle
Common Shares, no par value
dei Trading Symbol
TradingSymbol
ACOG
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15531282 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3666389 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1404160 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
107010 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
90413 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
740933 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
366316 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4514332 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1918439 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
80000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1011 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1721 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
432729 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
532010 usd
CY2024Q3 us-gaap Assets
Assets
5028072 usd
CY2023Q4 us-gaap Assets
Assets
2452170 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1743596 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1394117 usd
CY2024Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
50777 usd
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
10413 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3005836 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2615993 usd
CY2024Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1002874 usd
CY2024Q3 acog Conversion Feature Liability
ConversionFeatureLiability
1415265 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2449478 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4455747 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74250 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84125 usd
CY2024Q3 us-gaap Liabilities
Liabilities
7947703 usd
CY2023Q4 us-gaap Liabilities
Liabilities
7155865 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6034216 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6034216 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4728355 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4728355 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
49149464 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
39760287 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
62 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
62 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18661446 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17288430 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104301 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104301 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70626302 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61648173 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2919631 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4703695 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5028072 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2452170 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
996029 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1429716 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2879945 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3773880 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1491755 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1336197 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6440568 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3744162 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2487784 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2765913 usd
us-gaap Operating Expenses
OperatingExpenses
9320513 usd
us-gaap Operating Expenses
OperatingExpenses
7518042 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2487784 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2765913 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7518042 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8217 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13301 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-29708 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3584 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1916 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2712 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
16146 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
5059 usd
CY2024Q3 us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
61122 usd
CY2023Q3 us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
32757 usd
us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
333462 usd
us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
32757 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
18679 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
9607 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
42153 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
14017 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
39166 usd
CY2024Q3 acog Changes In Fair Value Of Conversion Feature Liability
ChangesInFairValueOfConversionFeatureLiability
174930 usd
acog Changes In Fair Value Of Conversion Feature Liability
ChangesInFairValueOfConversionFeatureLiability
174930 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-416806 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
515771 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
16127 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
532429 usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
55000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
627878 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-503210 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
342384 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-512214 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1859906 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3269123 usd
us-gaap Net Income Loss
NetIncomeLoss
-8978129 usd
us-gaap Net Income Loss
NetIncomeLoss
-8030256 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11232 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19573 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1859906 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3280355 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8978129 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8049829 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.23
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6030259 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6030259 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3880433 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3880433 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5928460 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5928460 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3599266 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3599266 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1393466 usd
CY2024Q3 acog Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
140000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
193741 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1859906 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2919631 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-579426 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1345093 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-186050 usd
CY2023Q3 us-gaap Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
-4189576 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
697073 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-11232 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3269123 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-6193241 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4703695 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
3732469 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2273949 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-405753 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1800 usd
acog Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
300000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
917153 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3942575 usd
us-gaap Net Income Loss
NetIncomeLoss
-8978129 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2919631 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1320177 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
5851148 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-394736 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10500 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1899429 usd
us-gaap Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
-4189576 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-19573 usd
us-gaap Net Income Loss
NetIncomeLoss
-8030256 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-6193241 usd
us-gaap Net Income Loss
NetIncomeLoss
-8978129 usd
us-gaap Net Income Loss
NetIncomeLoss
-8030256 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
60825 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
63359 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-64101 usd
us-gaap Government Assistance Operating Expense
GovernmentAssistanceOperatingExpense
-23767 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-5476 usd
acog Accrue Interest Expense Convertible Debentures
AccrueInterestExpenseConvertibleDebentures
8716 usd
acog Reversal Of Accrued Interest Income Related Party
ReversalOfAccruedInterestIncomeRelatedParty
-2550 usd
acog Reversal Of Accrued Interest Income Related Party
ReversalOfAccruedInterestIncomeRelatedParty
886 usd
acog Change In Fair Value Of Conversion Feature Liability
ChangeInFairValueOfConversionFeatureLiability
174930 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
16127 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
532429 usd
acog Change In Fair Value Of Bonus Rights Liability
ChangeInFairValueOfBonusRightsLiability
-9875 usd
acog Change In Fair Value Of Bonus Rights Liability
ChangeInFairValueOfBonusRightsLiability
5246 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
354791 usd
us-gaap Provision For Other Losses
ProvisionForOtherLosses
55000 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
39166 usd
us-gaap Share Based Compensation
ShareBasedCompensation
917153 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1899429 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2273949 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
454617 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-68761 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
349478 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1312729 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5451927 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6769171 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3732469 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5851148 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1800 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10500 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
300000 usd
acog Proceeds Received From Restricted Government Grant
ProceedsReceivedFromRestrictedGovernmentGrant
373825 usd
acog Proceeds Received From Restricted Government Grant
ProceedsReceivedFromRestrictedGovernmentGrant
201500 usd
acog Amounts Paid From Restricted Government Grant Funds
AmountsPaidFromRestrictedGovernmentGrantFunds
357228 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
55000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4545000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
459360 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
405753 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
394736 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7730753 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5613412 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-19573 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2278826 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1175332 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1494573 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2083696 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3773399 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
908364 usd
CY2024Q3 us-gaap Deposit Assets
DepositAssets
3666389 usd
CY2023Q3 us-gaap Deposit Assets
DepositAssets
706864 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
107010 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
201500 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3773399 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
908364 usd
us-gaap Interest Paid Net
InterestPaidNet
37754 usd
us-gaap Interest Paid Net
InterestPaidNet
53991 usd
acog Reallocation Of Fair Value Of Share Options Upon Exercise
ReallocationOfFairValueOfShareOptionsUponExercise
126382 usd
acog Reallocation Of Fair Value Of Share Options Upon Exercise
ReallocationOfFairValueOfShareOptionsUponExercise
676632 usd
acog Reclassification Of Derivative Liability For Warrants Priced With Usd Per Change In Functional Currency
ReclassificationOfDerivativeLiabilityForWarrantsPricedWithUSDPerChangeInFunctionalCurrency
351969 usd
acog Reclassification Of Derivative Liability For Warrants Priced With Cad Per Change In Functional Currency
ReclassificationOfDerivativeLiabilityForWarrantsPricedWithCADPerChangeInFunctionalCurrency
4541545 usd
acog Reclassification Of Derivative Liability For Warrants Repriced From Cad To Usd Exercise Price
ReclassificationOfDerivativeLiabilityForWarrantsRepricedFromCADToUSDExercisePrice
3942575 usd
us-gaap Stock Issued1
StockIssued1
928874 usd
acog Warrants Issued For Share Issuance Costs
WarrantsIssuedForShareIssuanceCosts
582245 usd
acog Warrants Issued For Share Issuance Costs
WarrantsIssuedForShareIssuanceCosts
117310 usd
acog Common Shares Issued For Services
CommonSharesIssuedForServices
2273949 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alpha Cognition Inc. (“ACI” or the “Company”) is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s Disease and Cognitive Impairment with Traumatic Brain Injury (“TBI”), for which there are limited or no treatment options. The registered and records office of the Company is 1200 – 750 West Pender Street, Vancouver, BC, V6C 2T8. . As of November 12, 2024, the Company’s common shares commenced trading on the NASDAQ stock exchange under the symbol “ACOG”. As of May 1, 2023, the Company’s common shares commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “ACOG”, previously the Company’s shares were traded on the TSX Venture Exchange (“TSX-V”) until April 28, 2023, when the Company had them delisted. The Company’s shares also traded on the Over-The-Counter Markets (“OTC”) under the trading symbol “ACOGF” until they were listed on the NASDAQ.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 29, 2024, the Company was granted approval by the U.S. Food and Drug Administration (FDA) for the commercialization of ZUNVEYL, previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 5, 2024, the Company completed a reverse stock split on the ratio of one share issued for every previously issued and outstanding twenty-five shares. All current and comparative references to the number and price per share for common shares, preferred shares, options, warrants, ACI Canada legacy performance options and weighted average number of shares, loss per share, have been restated to give effect to this reverse stock split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2024, the Company completed a public offering of Common Shares by issuing 8,695,653 Common Shares at a public offering price of $5.75 per share for gross proceeds of $50,000,005. In connection with the US public offering, the Company’s Common Shares began trading on the NASDAQ on November 12, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited condensed interim consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The Company has not generated revenues from its operations to date and as of September 30, 2024, had working capital of $1,508,496 and an accumulated deficit of $70,626,302 which has been primarily financed by equity. The Company’s continuing operations, as intended, are dependent upon its ability to generate cash flows or obtain additional financing. Upon closing the Company’s $50 million financing on November 13, 2024, management is of the opinion that it does have sufficient working capital to meet the Company’s liabilities and commitments as they become due for the 12 months from the date these financial statements. Management intends to finance operating costs over the next twelve months with cash on hand.</p>
CY2024Q3 acog Working Capital
WorkingCapital
1508496 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70626302 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates and Assumptions</i> – </b>The preparation of these unaudited condensed interim consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the unaudited condensed interim consolidated financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, to ensure that those estimates effectively reflect changes in the Company’s business and new information as it becomes available. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results could differ materially from these estimates under different assumptions or conditions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk </i></b><i>– </i>The Company’s financial instruments subject to concentrations of credit risk consists primarily of cash and cash equivalents. Cash is deposited with financial institutions with high credit quality which are typically in excess of insured limits. Additionally, as of September 30, 2024, the Company had $231,887 (December 31, 2023 - $475,567) in cash held at its payment processing company in a demand account to be used to pay accounts payable. During the nine months ending September 30, 2024, and 2023, the Company did not experience any loss related to these concentrations.</p>
CY2024Q3 us-gaap Cash
Cash
231887 usd
CY2023Q4 us-gaap Cash
Cash
475567 usd
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
39166 usd
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.50 pure
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
11874 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
16099 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74250 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84125 usd
CY2024Q3 acog Fair Value Of Conversion Feature Liability
FairValueOfConversionFeatureLiability
1002874 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2449478 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4455747 usd
CY2024Q3 us-gaap Fair Value Concentration Of Risk Foreign Currency Contracts
FairValueConcentrationOfRiskForeignCurrencyContracts
31000 cad
CY2023Q4 us-gaap Fair Value Concentration Of Risk Foreign Currency Contracts
FairValueConcentrationOfRiskForeignCurrencyContracts
36000 cad
acog Change In Exchange Rate
ChangeInExchangeRate
0.10 pure
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
2200 usd
acog Grant Income
GrantIncome
333462 usd
acog Grant Income
GrantIncome
32757 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
107010 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
90413 usd
CY2024Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
50777 usd
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
10413 usd
us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
333462 usd
us-gaap Government Assistance Nonoperating Income
GovernmentAssistanceNonoperatingIncome
32757 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
333462 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
32757 usd
CY2023Q3 us-gaap Advances To Affiliate
AdvancesToAffiliate
150000 usd
CY2024Q3 us-gaap Advances To Affiliate
AdvancesToAffiliate
55000 usd
CY2023Q4 us-gaap Advances To Affiliate
AdvancesToAffiliate
55000 usd
CY2024Q3 us-gaap Principal Amount Outstanding On Loans Securitized
PrincipalAmountOutstandingOnLoansSecuritized
55000 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
4195 usd
CY2024Q3 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
24795 usd
CY2023Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
100036 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
710340 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
206377 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
5798 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
59903 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
740933 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
366316 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
80000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12370 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12370 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11359 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10649 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1011 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1721 usd
CY2024Q3 us-gaap Depreciation
Depreciation
236 usd
CY2023Q3 us-gaap Depreciation
Depreciation
525 usd
us-gaap Depreciation
Depreciation
710 usd
us-gaap Depreciation
Depreciation
1577 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
790310 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
475553 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
274955 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
127284 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
678331 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
791280 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1743596 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1394117 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1185633 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
432729 usd
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P5Y5M1D
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1235633 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
703623 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
532010 usd
CY2023 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P6Y7M9D
CY2024Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
19761 usd
CY2023Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
20594 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
60115 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
61782 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
39166 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
19761 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
79042 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
79042 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
79042 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
79042 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
96800 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
432729 usd
CY2015Q1 us-gaap Notes Payable
NotesPayable
1400000 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
1211463 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
1211463 usd
us-gaap Accretion Expense
AccretionExpense
59129 usd
us-gaap Accretion Expense
AccretionExpense
42982 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
300000 usd
CY2024Q2 acog Debt Instrument Due Date
DebtInstrumentDueDate
2024-12-31
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4545000 usd
acog Accretion Of Convertible Debt
AccretionOfConvertibleDebt
64101 usd
acog Accrued Interest Of Conveertible Debentures
AccruedInterestOfConveertibleDebentures
8716 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
104569 usd
acog Revaluation Of Conversion Feature Liability
RevaluationOfConversionFeatureLiability
-174930 usd
acog Revaluation Of Warrant Liabilities
RevaluationOfWarrantLiabilities
-124155 usd
CY2024Q3 us-gaap Convertible Debt
ConvertibleDebt
4214163 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
8716 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
64101 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
acog Gain On Revaluation Of Conversion Feature Liability
GainOnRevaluationOfConversionFeatureLiability
174930 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
354791 usd
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
1:1
us-gaap Stockholders Equity Other Shares
StockholdersEquityOtherShares
16000 shares
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
160000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1800 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
89631 usd
CY2023 us-gaap Payments For Commissions
PaymentsForCommissions
172480 usd
CY2023 us-gaap Legal Fees
LegalFees
15428 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1 shares
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1344480 usd
CY2023Q2 acog Aggregate Proceeds Percentage
AggregateProceedsPercentage
0.10 pure
CY2023Q2 us-gaap Product Warranty Liquidation Proceeds Percentage
ProductWarrantyLiquidationProceedsPercentage
0.10 pure
CY2023Q2 acog Gross Proceeds Percentage
GrossProceedsPercentage
0.05 pure
CY2023Q4 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2026-10-16
CY2023Q4 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2026-11-08
CY2023Q4 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2026-12-22
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3444 shares
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
80039 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
430807 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.55
CY2023Q3 acog Reclassification Of Charged To Equity
ReclassificationOfChargedToEquity
4541545 usd
CY2023Q3 us-gaap Investment Company Increase Decrease From Share Transaction
InvestmentCompanyIncreaseDecreaseFromShareTransaction
4541545 usd
CY2023 acog Repriced Of Warrants
RepricedOfWarrants
471093 shares
acog Reclassification Of Derivative Liability Per Change In Functional Currency
ReclassificationOfDerivativeLiabilityPerChangeInFunctionalCurrency
3942575 usd
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
140282 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0366 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0349 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y11M23D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
390161 usd
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6600 shares
CY2018Q3 us-gaap Payment For Management Fee
PaymentForManagementFee
13333 usd
CY2022Q3 us-gaap Fee Income
FeeIncome
7500 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
610946 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
672550 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
1211463 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
1211463 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
2561707 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
3150921 usd
CY2015Q1 acog Net Sales Revenue Percentage
NetSalesRevenuePercentage
0.03 pure
CY2015Q1 acog Sublicensing Revenue
SublicensingRevenue
0.10 pure
CY2015Q1 acog Milestone Payment
MilestonePayment
0.25 pure
CY2015Q1 acog Royalty Payment Percentage
RoyaltyPaymentPercentage
0.01 pure
CY2015Q1 us-gaap Revenues
Revenues
100000000 usd
CY2015Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1400000 usd
CY2016Q1 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
2142920 usd
CY2016Q1 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
2000000 eur
CY2016Q1 acog Net Sales Revenue Percentage
NetSalesRevenuePercentage
0.01 pure
CY2016Q1 acog Sublicensing Revenue
SublicensingRevenue
0.02 pure
CY2016Q1 acog Milestone Payment
MilestonePayment
0.02 pure
CY2020Q4 us-gaap Payments For Purchase Of Other Assets1
PaymentsForPurchaseOfOtherAssets1
50000 usd
CY2020Q4 acog Royalty Percentage
RoyaltyPercentage
0.015 pure
CY2020Q4 acog Commercial Sales
CommercialSales
2000000 usd
CY2020Q4 acog Milestone Payment
MilestonePayment
0.10 pure
CY2020Q4 acog Received Of Upfrontpayments
ReceivedOfUpfrontpayments
2000000 usd
CY2020Q4 acog License Agreement Terms
LicenseAgreementTerms
P11Y
CY2020Q4 us-gaap Other Notes Payable
OtherNotesPayable
2000000 usd
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
50000 usd
CY2023Q2 us-gaap Payments For Fees
PaymentsForFees
480000 usd
CY2023Q4 us-gaap Payments For Fees
PaymentsForFees
160000 usd
CY2024Q1 us-gaap Payments For Fees
PaymentsForFees
320000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1743596 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
1211463 usd
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
2955059 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1394117 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
1211463 usd
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
2605580 usd
CY2024Q3 us-gaap Financial Instruments Owned Other At Fair Value
FinancialInstrumentsOwnedOtherAtFairValue
433740 usd
CY2023Q4 us-gaap Financial Instruments Owned Other At Fair Value
FinancialInstrumentsOwnedOtherAtFairValue
533731 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1859906 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1859906 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3269123 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3269123 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8978129 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8978129 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8049256 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8049256 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6030259 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6030259 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3880433 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3880433 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5928460 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5928460 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3599266 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3599266 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.23
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4290779 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2394332 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 acog Non Rule10b51 Arrangement Modified Flag
NonRule10b51ArrangementModifiedFlag
false
CY2024Q3 acog Rule10b51 Arrangement Modified Flag
Rule10b51ArrangementModifiedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
usd
CY2023Q4 acog Conversion Feature Liability
ConversionFeatureLiability
usd
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2024Q3 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q4 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
us-gaap Operating Income Loss
OperatingIncomeLoss
-9320513 usd
CY2023Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2023Q3 acog Changes In Fair Value Of Conversion Feature Liability
ChangesInFairValueOfConversionFeatureLiability
usd
acog Changes In Fair Value Of Conversion Feature Liability
ChangesInFairValueOfConversionFeatureLiability
usd
CY2024Q3 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
usd
CY2023Q3 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
usd
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
usd
acog Adjustments To Additional Paid In Capital Warrant Expired
AdjustmentsToAdditionalPaidInCapitalWarrantExpired
usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
usd
us-gaap Government Assistance Operating Expense
GovernmentAssistanceOperatingExpense
usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
usd
acog Accrue Interest Expense Convertible Debentures
AccrueInterestExpenseConvertibleDebentures
usd
acog Change In Fair Value Of Conversion Feature Liability
ChangeInFairValueOfConversionFeatureLiability
usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
us-gaap Provision For Other Losses
ProvisionForOtherLosses
usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
acog Amounts Paid From Restricted Government Grant Funds
AmountsPaidFromRestrictedGovernmentGrantFunds
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
acog Reclassification Of Derivative Liability For Warrants Priced With Usd Per Change In Functional Currency
ReclassificationOfDerivativeLiabilityForWarrantsPricedWithUSDPerChangeInFunctionalCurrency
usd
acog Reclassification Of Derivative Liability For Warrants Priced With Cad Per Change In Functional Currency
ReclassificationOfDerivativeLiabilityForWarrantsPricedWithCADPerChangeInFunctionalCurrency
usd
acog Reclassification Of Derivative Liability For Warrants Repriced From Cad To Usd Exercise Price
ReclassificationOfDerivativeLiabilityForWarrantsRepricedFromCADToUSDExercisePrice
usd
us-gaap Stock Issued1
StockIssued1
usd
acog Common Shares Issued For Services
CommonSharesIssuedForServices
usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2023Q4 acog Fair Value Of Conversion Feature Liability
FairValueOfConversionFeatureLiability
usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7529043 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
usd
acog Allocation Of Proceeds To Conversion Feature Liability
AllocationOfProceedsToConversionFeatureLiability
usd
acog Allocation Of Proceeds To Warranty Liabilities
AllocationOfProceedsToWarrantyLiabilities
usd
acog Gain On Revaluation Of Conversion Feature Liability
GainOnRevaluationOfConversionFeatureLiability
usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001655923

Files In Submission

Name View Source Status
0001213900-24-098409-index-headers.html Edgar Link pending
0001213900-24-098409-index.html Edgar Link pending
0001213900-24-098409.txt Edgar Link pending
0001213900-24-098409-xbrl.zip Edgar Link pending
acog-20240930.xsd Edgar Link pending
ea0220014-10q_alpha.htm Edgar Link pending
ea022001401ex31-1_alpha.htm Edgar Link pending
ea022001401ex31-2_alpha.htm Edgar Link pending
ea022001401ex32-1_alpha.htm Edgar Link pending
ea022001401ex32-2_alpha.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
acog-20240930_def.xml Edgar Link unprocessable
acog-20240930_lab.xml Edgar Link unprocessable
acog-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0220014-10q_alpha_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acog-20240930_cal.xml Edgar Link unprocessable